Biotech giant Gilead Sciences (Nasdaq: GILD) has received approval from the US Food and Drug Administration (FDA) for its new treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.
Vemlidy (tenofovir alafenamide, TAF) will carry a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of HBV.
"Vemlidy is the first medication approved to treat this disease in nearly a decade"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze